Nab-paclitaxel + Carboplatin

DRUG3 trials

Sponsors

Hebei Medical University Fourth Hospital, Eikon Therapeutics

Conditions

Breast CancerNab-paclitaxelNon Small Cell Lung Cancer (Squamous or Non Squamous)Stage 4 NSCLCTriple Negative Breast CancerTriple-negative Breast Cancer

Phase 2

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

RecruitingNCT04138719

Hebei Medical University Fourth HospitalBreast Cancer, Nab-paclitaxel, Triple-negative Breast Cancer

Start: 2019-11-20End: 2028-06-20Target: 520Updated: 2025-09-11

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

RecruitingNCT04159142

Hebei Medical University Fourth HospitalNab-paclitaxel, Triple Negative Breast Cancer

Start: 2019-11-20End: 2028-09-20Target: 414Updated: 2025-09-11

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

Not yet recruitingNCT07365319

Eikon TherapeuticsNon Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC

Start: 2026-05-18End: 2040-12-31Target: 750Updated: 2026-01-26